|
業務類別
|
Biotechnology |
|
業務概覽
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
| 公司地址
| 195 Church Street, 16th Floor, New Haven, CT, USA, 06510 |
| 電話號碼
| +1 203 304-2499 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.trevitherapeutics.com |
| 員工數量
| 26 |
| Dr. James V. Cassella,PhD |
Chief Development Officer |
美元 120.00K |
29/04/2025 |
| Ms. Jennifer L. Good |
President, Chief Executive Officer and Director |
美元 607.93K |
29/04/2025 |
| Dr. Thomas R. Sciascia,M.D. |
Chief Scientific Officer |
-- |
29/04/2025 |
| Mr. Christopher Galletta |
Controller and Principal Accounting Officer |
-- |
18/03/2025 |
| Mr. Farrell Simon |
Chief Commercial Officer |
-- |
29/04/2025 |
| Mr. David C. Hastings |
Chief Financial Officer |
-- |
05/12/2025 |
|
|
| Ms. Anne M. Vanlent |
Independent Director |
29/04/2025 |
| Dr. David P. Meeker,M.D. |
Chairman of the Board |
29/04/2025 |
| Mr. Dominick C. Colangelo |
Independent Director |
29/04/2025 |
| Mr. Edward T. Mathers |
Independent Director |
29/04/2025 |
| Ms. Jennifer L. Good |
President, Chief Executive Officer and Director |
29/04/2025 |
| Mr. Michael T. Heffernan, R.Ph. |
Independent Director |
29/04/2025 |
|
|
|
|
